US2011160445A1PendingUtilityA1

Heparin-Binding Growth Factor (HBGF) Polypeptides

Assignee: CHILDRENS HOSP RES FOUNDATIONPriority: Aug 7, 1997Filed: Feb 28, 2011Published: Jun 30, 2011
Est. expiryAug 7, 2017(expired)· nominal 20-yr term from priority
A61P 43/00A61P 9/10A61P 9/00C07K 16/24C07K 14/475C07K 2317/34A61K 38/00A61P 15/00A61P 17/02Y10S930/12A61P 21/00Y10S530/85C07K 16/22A61P 19/00
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Substantially pure heparin-binding growth factor polypeptides (HBGFs), nucleic acids encoding the HBGFs and antibodies which bind to the HBGFs of the invention are provided. The HBGF polypeptides axe useful in methods for the induction of bone, cartilage and tissue formation, growth and development of the endometrium and in the acceleration of wound healing.

Claims

exact text as granted — not AI-modified
1 . An antisense molecule to a nucleic acid encoding heparin-binding growth factor (HBGF) polypeptide, wherein the amino acid sequence of the HBGF polypeptide is an amino acid sequence of the carboxy terminal of a human connective tissue growth factor (CTGF) protein from amino acid residue 247 to residue 349, wherein the amino terminal sequence of HBGF begins with SEQ ID NO:1; or wherein the amino acid sequence of the HBGF polypeptide is an amino acid sequence of the carboxy terminal of a human CTGF protein from amino acid residue 248 to residue 349, wherein the amino terminal sequence of HBGF begins with SEQ ID NO:2. 
     
     
         2 . The antisense molecule of  claim 1 , wherein the molecule is between 15 and 25 nucleotides in length. 
     
     
         3 . Use of the antisense molecule of  claim 1  for affecting wound healing, tissue formation, sclerotic or cell proliferative disorders, atherosclerosis or fibrotic disease.

Join the waitlist — get patent alerts

Track US2011160445A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.